Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T in R/R CD19+ B-Cell Leukemia and Lymphoma
NCT04271800Phase 2Unknown
- Sponsor
- Chongqing Precision Biotech
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in B-cell leukemia (BCL), B cell lymphoma, chronic lymphocytic leukemia (CLL) and 1 more, sponsored by Chongqing Precision Biotech. Primary endpoints: Adverse events related to treatment at 2 years and Response rate of CD19 CAR-T treatment at 6 months. Status: unknown.
02
Drugs
CD19 CAR-T cells
03
Conditions
B-cell leukemia (BCL)B cell lymphomachronic lymphocytic leukemia (CLL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04271800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04271800.